Ritter Pharmaceuticals, Inc. (RTTR) Releases Quarterly Earnings Results, Hits Estimates
Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) posted its earnings results on Monday. The biotechnology company reported ($0.14) earnings per share for the quarter, hitting the consensus estimate of ($0.14), Bloomberg Earnings reports.
Shares of Ritter Pharmaceuticals (NASDAQ:RTTR) traded down 1.9667% during trading on Tuesday, reaching $0.5882. 74,470 shares of the company traded hands. The company’s market capitalization is $8.60 million. The company’s 50-day moving average price is $0.58 and its 200-day moving average price is $1.53. Ritter Pharmaceuticals has a 52 week low of $0.50 and a 52 week high of $3.75.
COPYRIGHT VIOLATION NOTICE: This article was first posted by Daily Political and is the sole property of of Daily Political. If you are viewing this article on another publication, it was stolen and reposted in violation of US and international copyright law. The original version of this article can be viewed at https://www.dailypolitical.com/2017/08/08/ritter-pharmaceuticals-inc-rttr-releases-quarterly-earnings-results-hits-estimates.html.
Several equities analysts have recently weighed in on the stock. Maxim Group reiterated a “hold” rating on shares of Ritter Pharmaceuticals in a research note on Friday. Chardan Capital reduced their target price on shares of Ritter Pharmaceuticals from $3.50 to $1.50 and set a “buy” rating for the company in a research note on Tuesday. Finally, Zacks Investment Research downgraded shares of Ritter Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday. Two analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $4.88.
Ritter Pharmaceuticals Company Profile
Ritter Pharmaceuticals, Inc develops therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. The Company’s segment is focusing on the development and commercialization of RP-G28. The Company conducts human gut health research by exploring metabolic capacity of the gut microbiota and translating the functionality of prebiotic-based therapeutics into applications intended to have impact on a patient’s health.
Receive News & Ratings for Ritter Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ritter Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.